ArticleDiscover oncology2026
The prognostic value of miR-323b-5p in non-small cell lung cancer and its mechanism of targeting IL1A in regulating the proliferation and cell cycle of non-small cell lung cancer cells.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA (miRNA) plays a crucial role in initiating and progressing non-small cell lung cancer (NSCLC).
aimThis study aims to investigate the expression and prognostic value of miR-323b-5p in NSCLC patients, and to clarify the mechanisms of miR-323b-5p and IL1A on the proliferation and cell cycle of NSCLC cells.
methodsDifferentially expressed miRNAs were screened from the GSE171517 dataset. 120 NSCLC patients and 60 healthy controls were collected. RT-qPCR was used to detect miR-323b-5p and interleukin 1α (IL1A). Prognostic value was analyzed via Kaplan-Meier and Cox regression. Target genes of miR-323b-5p were predicted using TargetScan/miRDB and validated by dual-luciferase assay. Cell proliferation was detected by cell counting kit-8 (CCK-8). Cell cycle was detected by flow cytometry. The expression of cyclin-dependent kinase inhibitor 1 A (P21), cyclin D1 (CCND1) and cyclin dependent kinase 4 (CDK4) was detected by western blot and RT-qPCR.
resultsmiR-323b-5p was significantly downregulated in NSCLC serum samples and A549, HCC827, and NCI-H1299 cell lines. Low miR-323b-5p correlated with poorer 5-year survival rate and was a prognostic risk factor for NSCLC. IL1A was a direct target of miR-323b-5p. miR-323b-5p mimics can inhibit the proliferation of A549, HCC827, and NCI-H1299 cells, arrest the cell cycle to the S phase, promote P21, and inhibit the expression of CCND1 and CDK4. Overexpression of IL1A can partially reverse the above phenomena.
conclusionsLow levels of miR-323b-5p predict a poor prognosis for NSCLC. miR-323b-5p regulates the cell cycle of NSCLC cells by targeting IL1A, thereby inhibiting cell proliferation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.